首页> 中文期刊>中国现代药物应用 >2种长效胰岛素类似物的研究进展

2种长效胰岛素类似物的研究进展

     

摘要

胰岛素(insulin, INS)首次用于治疗糖尿病以来,随着对糖尿病病理和生理以及发病机制的深入研究,胰岛素得到了许多糖尿病患者的认可。随着重组DNA技术的发展,出现了一批新的长效胰岛素类似物:地特胰岛素(detemir)和德谷胰岛素(degludec)。它们在注射后均可以模拟人胰岛素的分泌方式,持续少量的释放,使餐前和餐后以及夜间的血糖保持稳定;但是随着各方面的深入研究,它们在分子结构、作用机制、生产工艺以及临床应用方面存在着许多不同之处。%With the research of the pathophysiology and pathogenesis of diabetes, insulin (INS) had been widely used in the treatment of diabetes. And a number of new long-acting insulin analogues appeared with the development of recombination DNA technology, which could simulate normal basal secretion of insulin. Therefore, the blood sugar level could be kept stable between the intervals of meals or during the night. Insulin detemir and insulin degludec were two novel long-acting insulin analogues in the treatment of diabetes. This review presents the differences between Insulin detemir and insulin degludec in molecular structure, long-term mechanism of action, production process and clinical application.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号